Nikolas Toleris

Panmure Gordon (UK) Ltd. (PGL) is the stockbroking subsidiary of Panmure Gordon & Co. Ltd. in Great Britain. Headquartered in London, the firm was founded in 2003 and provides corporate finance advice, distributes and trades securities and produces investment research to UK small and mid-cap corporates and investment companies. PGL has access to capital markets via a range of equity and equity-linked products such as IPOs, accelerated book buildings, placings, rights issues, and bought deals. The firm's institutional equities department provides UK-focused research, sales and trading services to institutional investors in the UK, US and Europe.

Guinness Asset Management Ltd., dba Guinness Global Investors (Guinness), is an independent fund manager headquartered in London, UK. The firm was founded by Timothy "Tim" Guinness in 2003. They provide actively managed portfolios in a selection of asset classes and specialist growth themes to assist investors in achieving their investment goals. Guinness is a signatory to the UN Principles for Responsible Investment (UN PRI).

Mirabaud Asset Management Ltd. (MAM) is the Great Britain-based subsidiary of Mirabaud SCA, itself a wholly-owned subsidiary of Mirabaud Partners & Cie in Switzerland. The firm was founded by Philip Watson in 1982 as TWH Management, later taken over by Mirabaud Pereire Holdings. Headquartered in London, MAM provides a focused and specialized range of investment solutions to institutional and wholesale investors on a global basis.

Commerzbank AG (UK) is the UK brokerage division of Commerzbank AG (FR: CBK) in Germany. Based in London, they engage in equity, debt and derivative instrument trading, investment banking, public finance and treasury, interest-rate and currency management, as well as corporate finance. In 2009 Dresdner Bank was acquired by and merged into Commerzbank and the London-based activities of Dresdner Kleinwort Securities absorbed into Commerzbank AG (UK). The firm provides capital markets services, corporate advisory, risk management, research and lending services focused on equity, corporate and emerging-market debt, derivatives and money market products. Their clients are European and international corporations, institutions and government entities. In terms of corporate finance they offer financial advisory as well as execution capabilities for a wide range of corporate finance-related transactions on a global basis. Their primary focus is on mergers and acquisitions, disposals, equity issues and initial public offerings.

Morgan Stanley & Co. International Plc (MSCI) is a brokerage firm headquartered in London, UK. The firm was founded in 1986 and is a subsidiary of Morgan Stanley Investments (UK), ultimately held by Morgan Stanley (NYSE: MS) in the US. MSCI provides a range of brokerage services to corporations, governments and financial institutions.

Part of MF Global Holdings Ltd., MF Global UK Ltd. is a company that provides brokerage services. The company is based in London, UK.

Canaccord Genuity Ltd. (CGL) is the brokerage subsidiary of Canaccord Genuity Group, Inc. (TSE: CF). The firm is headquartered in London and was founded in 1983. CGL provides brokerage services to their clients.

Part of Mirabaud Partners & Cie, Mirabaud (Middle East) Ltd. is an Emirati company that provides investment banking services. The company is based in Dubai, United Arab Emirates.

Rutherford Health Plc is a holding company, which engages in the provision of cancer treatment research and technology services. It operates oncology centers that offers a range of cancer treatments to patients including radiotherapy, chemotherapy, imaging, and ancillary well-being services. The company was founded by Michael Moran and Karol Sikora on February 4, 2015 and is headquartered in Hereford, the United Kingdom.

Part of Clatterbridge Cancer Centre NHS Foundation Trust, Rutherford Cancer Care Ltd. operates as a trust for healthcare. The company is based in London, UK. The British company was founded in 2017. Rutherford Cancer Care was acquired by Clatterbridge Cancer Centre NHS Foundation Trust on April 06, 2023.